At Retrophin, we are brought together by our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. As we face the challenges presented by the coronavirus (COVID-19), the continued pursuit of this mission is ever more important.

We extend our thoughts and well wishes to the individuals and communities who have already been affected.

The health and safety of our employees, patients and caregivers remains our top priority. We recognize that this situation will continue to evolve, and we will continue to follow guidance from the World Health Organization (WHO) Centers for Disease Control and Prevention (CDC), as well as local public health authorities.

We have implemented proactive measures in an effort to best safeguard our employees and organization so that our work on behalf of patients can continue. These include travel restrictions, limited gatherings and a remote work environment. We also recognize our responsibility to ensure access and support for the many patients who are receiving our approved therapies or participating in our clinical studies. As such, we have taken precautionary measures to have additional access to inventory of our approved and investigational therapies, in an effort to prevent the interruption of clinical supply to patients participating in our clinical trials, and to maintain continued support and delivery of our approved therapies to our patients.

We know that rare diseases do not wait for pandemics like coronavirus, and our organization remains steadfast in its dedication to serving our patients and caregivers. We are continuously inspired by the rare disease community and we are thankful for the ongoing collaboration of our partners, patient advocates, clinical investigators, healthcare providers and the many others who are all coming together to support patients and their families during this period.

We wish you, your organization and community well. By embracing our global interconnectedness and helping others during this challenging time, we will ultimately emerge from this situation as a stronger community.

Take care and stay safe,

Eric Dube, Ph.D.
President and CEO
Retrophin, Inc.